NASDAQ: CYCCCyclacel Pharmaceuticals Inc Stock
$0.37+0.02 (+5.71%)
Updated Jan 24, 2025
CYCC Price
$0.37
Fair Value Price
N/A
Market Cap
$2.33M
52 Week Low
$0.31
52 Week High
$4.00
P/E
-0.04x
P/B
-2.4x
P/S
26.41x
PEG
N/A
Dividend Yield
N/A
Revenue
$74.00k
Earnings
-$13.43M
Gross Margin
100%
Operating Margin
-21,363.51%
Profit Margin
-18,217.6%
Debt to Equity
-6.55
Operating Cash Flow
-$11M
Beta
0.85
Next Earnings
Mar 17, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CYCC Overview
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CYCC's potential to beat the market
- CYCC doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CYCC
RankedUnranked of 555
RankedUnranked of 555
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.17 | A | |
| $122.04 | A | |
| $2.96 | A |
Be the first to know about important CYCC news, forecast changes, insider trades & much more!
CYCC News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CYCC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CYCC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CYCC is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
CYCC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more CYCC due diligence checks available for Premium users.
Valuation
CYCC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.04x
Industry
-188.16x
Market
30.33x
CYCC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.4x
Industry
5.04x
CYCC's financial health
Profit margin
Revenue
$10.0k
Net Income
-$2.0M
Profit Margin
-19,570%
CYCC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CYCC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$5.4M
Liabilities
$6.4M
Debt to equity
-6.55
CYCC's short-term liabilities ($6.35M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CYCC's short-term assets ($4.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CYCC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CYCC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.1M
Investing
$0.0
Financing
-$1.0k
CYCC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CYCC vs Biotech Stocks
Cyclacel Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.